Can pharmacotherapy improve treatment outcomes in people with co-occurring major depressive and cocaine use disorders?
Can pharmacotherapy improve treatment outcomes in people with co-occurring major depressive and cocaine use disorders?
复制标题
DOI：
10.1080/14656566.2021.1931684
复制
发表时间：
2021-09
影响因子：
3.2
通讯作者：
Potenza MN
中科院分区：
文献类型：
--
作者：
Angarita GA;Hadizadeh H;Cerdena I;Potenza MN
重度抑郁症 (MDD) 和可卡因使用障碍 (CUD) 很普遍，并且经常同时发生。当同时发生时，一种疾病的存在通常会对另一种疾病的预后产生负面影响。鉴于临床相关性，我们试图检查同时发生的 CUD 和 MDD 的药物疗法。虽然在每种疾病的治疗中都对多种治疗方案进行了单独检查，但探索其合并症的药理学方案的研究较少，而且还没有结论性的。在这篇综述中，作者使用与每种病症相关的疗法和关键词的临床查询选项在 PubMed 中搜索了文献。然后，他们根据两种疾病之间的共同机制和/或迄今为止进行的个体临床试验的结果描述了潜在有前途的药物治疗选择。兴奋剂、多巴胺 (D3) 受体部分激动剂或拮抗剂、κ 阿片受体拮抗剂、托吡酯和氯胺酮等药物可能很有前途，因为与奖励缺乏模型、抗奖励途径和改变的谷氨酸能系统相关的显着重叠。然而，关于这些类型的任何一种药物的现有临床文献都是混杂的。此外，对于某些药物，可能存在滥用可能性（例如氯胺酮和兴奋剂）。
Major depressive disorder (MDD) and cocaine use disorder (CUD) are prevalent and frequently co-occur. When co-occurring, the presence of one disorder typically negatively impacts the prognosis for the other. Given the clinical relevance, we sought to examine pharmacotherapies for co-occurring CUD and MDD. While multiple treatment options have been examined in the treatment of each condition individually, studies exploring pharmacological options for their comorbidity are fewer and not conclusive. For this review, the authors searched the literature in PubMed using clinical query options for therapies and keywords relating to each condition. Then, they described potentially promising pharmacologic therapeutic options based on shared mechanisms between the two conditions and/or results from individual clinical trials conducted to date. Medications like stimulants, dopamine (D3) receptors partial agonists or antagonists, antagonists of kappa opioid receptors, topiramate, and ketamine could be promising as there is significant overlap relating to reward deficiency models, anti-reward pathways, and altered glutamatergic systems. However, the available clinical literature on any one of these types of agents is mixed. Additionally, for some agents there is possible concern related to abuse potential (e.g., ketamine and stimulants).
登录
查看更多内容
氯胺酮和快速作用的抗抑郁药：介绍新的神经生物学的窗口，用于情绪障碍疗法。
影响因子：
10.5
作者：
Abdallah CG;Sanacora G;Duman RS;Krystal JH
通讯作者：
Krystal JH
DOI：
10.1017/s1461145712000661
发表时间：
2013-03
期刊：
The international journal of neuropsychopharmacology
影响因子：
--
作者：
Bergman J;Roof RA;Furman CA;Conroy JL;Mello NK;Sibley DR;Skolnick P
通讯作者：
Skolnick P
影响因子：
2.9
作者：
Bruchas MR;Land BB;Chavkin C
通讯作者：
Chavkin C
影响因子：
4.7
作者：
Bolloni C;Panella R;Pedetti M;Frascella AG;Gambelunghe C;Piccoli T;Maniaci G;Brancato A;Cannizzaro C;Diana M
通讯作者：
Diana M
DOI：
10.1111/add.15242
发表时间：
2021-04
期刊：
Addiction (Abingdon, England)
影响因子：
--
作者：
Brandt L;Chao T;Comer SD;Levin FR
通讯作者：
Levin FR